Document:

Employment Agreement between Linda K. Massman and Clearwater Paper Corporation

 Exhibit 10.2 
 [Letterhead of Clearwater Paper Corporation] 
 December 9, 2011 

Ms. Linda K. Massman 
 Dear Linda:

 The purpose of this letter agreement (this “Agreement”) is to confirm important terms and conditions pertaining to
your employment as President and Chief Operating Officer of Clearwater Paper Corporation (the “Company”) and supersedes in its entirety the terms and conditions of that offer letter dated August 26, 2008 from the Company
as successor in interest under that offer letter to Potlatch Corporation. 
 1. Term of Agreement: This Agreement shall be effective as
of November 1, 2011 (the “Effective Date”), and, unless terminated earlier in accordance with its terms, shall remain in effect for one (1) year following the Effective Date (the “Agreement
Term”). The Agreement Term shall automatically extend for successive one-year periods unless and until the Company gives, or you give, written notice to the other of termination at least ninety (90) calendar days prior to the end
of the then-current term. 
 2. Position: You will be employed with the Company as its President and Chief Operating Officer. You will
continue to serve as the Company’s Chief Financial Officer until your replacement is identified and elected. 
 3. Base Salary: Your
base salary as of the Effective Date is $525,000 on an annualized basis, payable in accordance with the Company’s regular payroll practices, as established from time to time. Beginning on March 1, 2013 and continuing thereafter during the
term of this Agreement, your salary shall be reviewed on at least an annual basis by, and may be increased but not decreased at the discretion of, the appropriate committee of the Board. Except as otherwise provided in this Section 3, the
review of your base salary will occur at the same time as the review for other senior executives of the Company. 
 4. Annual Incentive Award
Opportunity: You will be eligible to participate in the Company’s annual bonus plan for similarly situated executives. As of the Effective Date, your target annual bonus is 70% of your base salary. All awards shall be governed by the terms
of, and subject to any conditions established by, the Company’s then-current annual bonus plan. 
 5. Long-Term Incentive Awards:
You will be eligible to participate in the Company’s Long-Term Incentive Plan (“LTIP”), subject to the terms and conditions of the LTIP and on a basis at least as favorable as generally applicable to the other senior
executives of the Company. Under the current LTIP, beginning with the award granted in 2012, the target value of your LTIP 

 award is 125% of the mid-point of the range for your salary grade. Beginning with the award granted in 2012
and until changed, all of your LTIP awards will be granted in the form of performance shares. 
 6. Employee Benefits: 

(a) You will be eligible to participate in the Company’s employee welfare, benefit, and retirement plans and
programs, including retirement and supplemental retirement plans, on the same basis as generally applicable to the other senior executives of the Company. Further, you will be eligible for all fringe benefits and perquisites generally available to
the other senior executives of the Company on at least as favorable a basis as such other senior executives, and you will be reimbursed for reasonable business expenses per Company policy. 

(b) The Company will pay, or reimburse you for, the reasonable professional fees and related expenses you incur for legal
advice in connection with the preparation and execution of this Agreement. 
 7. Termination of Employment; Severance: This Agreement and
your employment with the Company may be terminated at any time during its term by either you or the Company, provided, however, that the parties’ rights and obligations upon such termination during the term shall be as set forth in applicable
provisions of this Agreement and the Severance Program for Executive Employees, as amended from time to time, or any successor program (the “Severance Program”) and applicable provisions of any other documents referenced in
Section 16 below. Termination of your employment for any reason shall constitute your resignation as an officer of the Company, its subsidiaries, and its affiliates. You will be a participant in the Severance Program and will be subject to all
the terms and conditions of the Severance Program, which are incorporated into this agreement by reference; provided, however, that: 
 (a) With regard to Section 4(a)(i) and the last paragraph of Section 4(a) and subject to Section 5(c) of the Severance Program (and any similar or successor sections), the cash benefit
payable upon the occurrence of any of the events specified in Section 5(a) of the Severance Program (and any similar or successor section) prior to a Change of Control (as that term is defined in the Severance Program) will be equal to one year
of your Base Compensation. 
 (b) Section 4(c) of the Severance Program (and any similar or successor
section) and references to Section 4(c) in Section 4(d) of the Severance Program (and any similar or successor section) shall not apply to you, and in their place the following provisions shall apply: 

(i) Notwithstanding any other provision of this Agreement, in the event that you become entitled to receive or receive any
payments, options, awards or benefits (including, without limitation, the monetary value of any non-cash benefits and the accelerated vesting of stock options) under this Agreement, the Severance Program or under any other plan, agreement or
arrangement with the Company, any person whose actions result in a “Change of Control” (as that term is defined in the Severance Program) or any person affiliated with the Company or such person (collectively, the
“Payments”), 

 
that may separately or in the aggregate constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the
“Code”), and the Treasury regulations promulgated thereunder (“280G”) and it is determined that, but for this Section 7(a), any of the Payments will be subject to any excise tax pursuant to
Section 4999 of the Code or any similar or successor provision (the “Excise Tax”), the Company shall pay to you either (i) the full amount of the Payments or (ii) an amount equal to the Payments, reduced by the
minimum amount necessary to prevent any portion of the Payments from being an “excess parachute payment” (within the meaning of Section 280G) (the “Capped Payments”), whichever of the
foregoing amounts results in the receipt by you, on an after-tax basis, of the greatest amount of Payments notwithstanding that all or some portion of the Payments may be subject to the Excise Tax. For purposes of determining whether you would
receive a greater after-tax benefit from the Capped Payments than from receipt of the full amount of the Payments and for purposes of Section 7(c) (if applicable), you shall be deemed to pay federal, state and local taxes at the highest
marginal rate of taxation for the applicable calendar year. 
 (ii) All computations and determinations called
for by Sections 7(i) and 7(iii) shall be made and reported in writing to the Company and you by a third-party service provider selected by the Company (the “Tax Advisor”), and all such computations and determinations
shall be conclusive and binding on the Company and you. For purposes of such calculations and determinations, the Tax Advisor may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The
Company and you shall furnish to the Tax Advisor such information and documents as the Tax Advisor may reasonably request in order to make their required calculations and determinations. The Company shall bear all fees and expenses charged by the
Tax Advisor in connection with its services. 
 (iii) In the event that Section 7(i) applies and a reduction
is required to be applied to the Payments thereunder, the Payments shall be reduced by the Company in a manner and order of priority that provides you with the largest net after-tax value; provided that payments of equal after-tax present value
shall be reduced in the reverse order of payment. Notwithstanding anything to the contrary herein, any such reduction shall be structured in a manner intended to comply with Section 409A of the Code. 

Further, and subject to Section 5(c) of the Severance Program (and any similar or successor section), upon the occurrence of any of the events
specified in Section 5(a) of the Severance Program (and any similar or successor section) prior to a Change of Control (as that term is defined in the Severance Program), you will receive a pro-rated settlement of your performance awards based
on actual performance determined pursuant to such plan and pro-rated vesting of your restricted stock unit awards, where applicable, granted under the LTIP. 
 Further, and subject to Section 5(c) of the Severance Program (and any similar or successor section), upon the occurrence of any of the events specified in Section 5(a) of the Severance Program
(and any similar or successor section) prior to a Change of Control (as that term is defined in the Severance Program), you shall receive a cash payment of $225,000. 

 8. Covenants: 
 You acknowledge and agree to execute and comply with the Company’s Inventions, Trade Secrets and Confidentiality Agreement, which is incorporated into this Agreement by reference, in the form
attached to this Agreement and as the same may be amended from time to time. You also acknowledge that your obligations under the Inventions, Trade Secrets and Confidentiality Agreement will survive the termination of your employment for any reason.
You also acknowledge and agree that you will have access to confidential and proprietary information of the Company and third parties in the course of performing your responsibilities for the Company, that such access is necessary to your ability to
perform those responsibilities, that such Company confidential and proprietary information is a valuable asset of the Company, and that the Company has developed and will develop goodwill that is a valuable asset of the Company. In view of the
foregoing and in consideration of the compensation and benefits as provided under this Agreement, you further agree that: 
 (a) during the time you are employed and for a period of two (2) years following your separation from employment with the Company for any reason, you will not, without the prior written consent of
the Company, directly or indirectly, engage in, whether as an owner, consultant, employee, or otherwise, activities competitive with that of the Company in any state, province or like geography where the Company does business; 

(b) during the time you are employed and for a period of two (2) years following your separation from employment with
the Company for any reason, you will not, without the prior written consent of the Company, directly or indirectly, solicit for employment, offer, or cause to be offered employment, either on a full time, part-time or consulting basis, to any person
who was employed by the Company or its affiliates on the date your employment terminated and with whom you had regular contact during the course of your employment by the Company; and 

(c) during the time you are employed and for a period of one (1) year following your separation from employment with
the Company for any reason, you will not, without the prior written consent of the Company, directly or indirectly, (A) solicit, divert, appropriate to or accept on behalf of any competitor of the Company, or (B) attempt to solicit,
divert, appropriate to or accept on behalf of any competitor of the Company, any business from any customer or actively sought prospective customer of the Company with whom you have dealt, whose dealings with the Company have been supervised by you
or about whom you have acquired confidential information in the course of your employment. 
 You agree that the foregoing restrictions are
reasonable, will not preclude you from finding gainful employment, and are necessary to protect the goodwill, confidential information, and other protectable business interests of the Company. You further agree that the Company would suffer
irreparable harm should you violate these restrictions and agree that injunctive relief, in addition to any other damages or relief available to the Company, is appropriate and necessary to protect the Company’s interests. 

9. Representation and Warranties: You represent and warrant that you are not a party to, or otherwise subject to, any covenant not to compete, or
other agreement that would restrict or limit 

 
your ability to perform your responsibilities under this Agreement, with any person or entity and that your performance of your obligations under this Agreement will not violate the terms and
conditions of any contract or obligation, written or oral, between you and any other person or entity. 
 10. Assignment and Successors:
This Agreement is personal to you and, without the prior written consent of the Company, shall not be assignable by you. The Company may assign this Agreement (a) to any corporation resulting from any merger, consolidation or other
reorganization to which the Company is a party; (b) any corporation, partnership, association or other person to which the Company may transfer all or substantially all of the assets and business of the Company existing at such time; or
(c) any subsidiary, parent or other affiliate of the Company. This Agreement shall inure to the benefit of and be enforceable by the Company and its successors and assigns. 
 11. Withholding: The Company may withhold from any payment that is required to be made under this Agreement amounts sufficient to satisfy applicable withholding requirements under any federal,
state, or local law and all payments hereunder shall be subject to applicable deductions. 
 12. Controlling Law: Except where otherwise
provided for herein, this Agreement shall be governed in all respects by the laws of the State of Washington, excluding any conflict-of-law rule that might refer the construction of the Agreement to the laws of another state or country. You consent
to the exclusive jurisdiction of the state and federal courts located in Spokane County, Washington, for any action relating to this Agreement. You will not bring any action relating to this Agreement in any other court. 

13. Notices: Any notices under this Agreement that are required to be given to the Company shall be addressed to the Corporate Secretary of the
Company, and any notices required to be given to you shall be sent to your address as shown in the Company’s records, which you are responsible for keeping up-to-date. 
 14. Separability and Construction: If any provision of this Agreement is determined to be invalid, unenforceable, or unlawful by a court of competent jurisdiction, the other provisions of this
Agreement shall remain in full force and effect, and the provisions that are determined to be invalid, unenforceable, or unlawful will either be limited or reformed so that they will remain in effect to the fullest extent allowed by law. 

15. Waiver of Breach: Except as otherwise specifically provided for herein, no failure by any party to give notice of any breach of, or to require
compliance with, any condition or provision of this Agreement shall be deemed a waiver or relinquishment of that party’s rights, and no waiver or relinquishment of rights by any party at any one or more times will be deemed to be a waiver or
relinquishment of such right or power at any other time or times. 
 16. Entire Agreement/Modification in Writing: This Agreement
together with the Inventions, Trade Secrets and Confidentiality Agreement, plan documents, grant notices, and governing policies of the Company (each as it may be amended from time to time) constitute the entire understanding relating to the matters
addressed herein and supersede any other prior 

 
agreement, whether written or oral. No addition to, or modification of, this Agreement shall be effective unless in writing and signed by both you and an authorized representative of the Company.

 17. Construction: Each party and his, her, or its counsel have reviewed this Agreement and have been provided the opportunity to
revise this Agreement, and, accordingly, the normal rule of construction providing for any ambiguities to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. Instead, the language of all parts of
this Agreement shall be construed as a whole and according to its fair meaning, not strictly for or against either party. Nothing in this Agreement is intended to or constitutes a guarantee of employment for a fixed or specific term, and the Company
reserves the right to adopt, amend, discontinue, or otherwise alter its compensation, benefit, and human resources practices, policies, and programs at its discretion. 
 18. Survival: The provisions of Sections 7, 8, 9 and 11-17 of this Agreement shall survive the termination of this Agreement and any termination of your employment hereunder. 

[Remainder of page intentionally left blank.] 

 Linda, I hope this Agreement provides you with the level of security and incentive that will allow you to
continue to contribute substantially to the success of the Company. Please sign below and return an executed original to me to indicate your acceptance of these terms. Again, we are pleased to have you as a continuing member of the team. 

Sincerely, 
  

	
	  

	 Gordon L. Jones
 Chief
Executive Officer

 cc: Thomas H. Carter 
 I, Linda K. Massman, have read, understand, accept and agree to the terms of the letter/agreement from Gordon L. Jones dated December 9, 2011. 

 

	
	  

	Linda K. Massman

                        
                , 2011 
 Date 

 Clearwater Paper Corporation 

Inventions, Trade Secrets and Confidentiality Agreement 
 IN CONSIDERATION OF and as a condition of my employment or continued employment by Clearwater Paper Corporation (the “Company”), and in consideration of the compensation and benefits to be
provided to me and the confidential and other information of the Company to which I will be provided access, I agree as follows: 

Inventions and Improvements 
  

	 	1.	I will keep adequate records regarding and will disclose to the Company all inventions or improvements made or conceived by me, solely or jointly with others, during my
employment with the Company and during the one-year period following the termination of my employment. 

  

	 	2.	I agree to assign and hereby do assign to the Company, without further compensation, my entire right in all such inventions and improvements, as well as any patent
applications or patents relating to them, except that my assignment and agreement to assign does not apply to an invention or improvement for which no equipment, supplies, facility, or trade secret information of the Company was used and which was
developed entirely on my own time, unless (a) the invention or improvement relates (i) directly to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development, or (b) the
invention or improvement results from any work performed by me for the Company. 

  

	 	3.	I will execute all papers, testify in any legal proceeding, and give any other assistance requested at any time by the Company to secure for the Company exclusive
rights in and patent or other protection in any country for all inventions and improvements that are assigned to the Company pursuant to this Agreement. In obtaining such assistance, the Company will make reasonable efforts, not inconsistent with
the Company’s timely obtaining the necessary assistance, to avoid materially impairing me in fulfilling my then-existing personal and professional commitments. I understand that if I am no longer employed by the Company, the Company will
reimburse me for my time spent providing this assistance. Reimbursement shall be at my regular base rate of compensation if I am employed elsewhere at the time I provide the assistance or, if I am not employed elsewhere at the time, at the regular
base rate of compensation that the Company was paying me as of the termination of my employment with the Company. 

  

	 	4.	I have attached to this Agreement a list describing all inventions, original works of authorship, developments, improvements, and trade secrets which were made by me
prior to my employment (collectively referred to as “Prior Inventions”), which belong to me or in which I have an interest, which relate to the Company’s current or proposed business, products or research and development, and which
are not assigned to the Company. I represent and warrant that this list is complete and accurate. If no list is attached, I represent and warrant that there are no Prior Inventions. 

 Trade Secrets and Confidential Information 

 

	 	5.	“Confidential Information” means any information related to the business or other affairs of the Company or its affiliates that is not generally available to
the public, and that: (a) is conceived, compiled, developed, or discovered by me whether solely or jointly with others, during my employment or (b) is or has been received or otherwise becomes known to me in connection with my employment.
Without limiting the generality of the foregoing, Confidential Information includes information, both written and oral, relating to inventions and improvements, trade secrets and other proprietary information, technical data, products, services,
finances, business plans, marketing plans, legal affairs, suppliers, clients, potential clients, prospects, opportunities, contracts or assets of the Company or its affiliates. Confidential Information also includes any information that has been
made available to the Company by its customers or other third parties and which the Company is obligated to keep confidential. 

  

	 	6.	I will not at any time, either during or after my employment by the Company, use or disclose any Company trade secrets or other Confidential Information except as
necessary to perform my duties to the Company, as authorized by the Company, or as required by law. 

  

	 	7.	I will, upon termination of my employment with the Company, or upon request, deliver to the Company all physical materials, including any writings, which relate to any
Company trade secrets or other Confidential Information or to any inventions or improvements transferred to the Company under this Agreement. This obligation includes materials in any form or format, whether paper, electronic or other.

  

	 	8.	I will not use in the performance of my work for the Company or disclose to the Company any trade secret or other confidential or proprietary information of any prior
employer or other person or entity if and to the extent that such use or disclosure may cause any breach, default or violation of any obligation or duty that I owe to such other person or entity (e.g., under any agreement or applicable law). My
compliance with this obligation will not prohibit, restrict or impair the performance of my work, obligations and duties to the Company. 

  

	 	9.	I consent to the Company providing a copy of this Agreement to any future employer or prospective employer of me. 

I understand and agree that (a) my obligations under this Agreement will survive the termination of my employment for any reason, (b) nothing
in this Agreement constitutes a promise of continued employment or a limitation on the Company’s or my rights to terminate my employment, (c) the Company may assign this Agreement to any entity that employs me, including but not limited to
any successor to the Company, (d) this Agreement will be governed by the laws of the State of Washington, and (e) any legal action relating to this Agreement shall be brought only in a state or federal court located in the State of
Washington. 
  

	
	  

	Employee’s Signature

	
	  

	Employee’s Printed Name
	
	
	Date

 (Upon execution, this document will be placed in the employee’s personnel file.)Form of RSU Deferral Agreement for Annual LTIP and Founders Grant RSUs

 Exhibit 10.3 
 Annual LTIP and Founders Grant RSUs 
 [Letterhead of Clearwater Paper
Corporation] 
 [Date] 
 [Name]

 [Address] 
 [Address] 

Re: Deferral of RSU Settlements 

Dear                     : 

You have                      Restricted Stock
Units (RSUs) scheduled to vest on December 31, 2011, and another                      RSUs (the balance of your “Founders
Award”) scheduled to fully vest on January 13, 2012. Ordinarily we would transfer to you the number of shares of Clearwater Paper common stock (“Shares”) corresponding to your fully vested RSUs within a period of days after the
vesting date. However, because the compensation from your RSUs will likely exceed the amount deductible by Clearwater Paper for federal income tax purposes, we are required to defer the delivery of a portion of these shares until a later date.

 The remainder of this letter explains in more detail the reasons for this deferral and how it will be administered in practice. 

Why must delivery of the Shares be deferred? 
 Section 12 of your RSU Agreements provides for an automatic deferral of RSU compensation to the extent that compensation would exceed the amount deductible by Clearwater Paper under
Section 162(m) of the Internal Revenue Code at the time the RSU award vests. 
 Section 162(m) imposes a $1 million cap on the tax
deduction that can be claimed by Clearwater Paper for compensation paid to any “covered employee” during a calendar year. Our “covered employees” for any calendar year are the CEO and the three most highly compensated executive
officers, other than the CFO, who are employed as of the end of the year. Performance-based compensation, such as our Performance Share awards and Annual Incentive Plan bonuses, is exempt from the $1 million limit, but RSUs are not considered
“performance-based” and thus are subject to the limit. 
 We are expecting that you will be one of our “covered employees”
for 2011 and 2012, and that your total non-performance based compensation for 2011 and 2012 will exceed the $1 million deduction limit. That means you will be subject to the deferral requirement. 

 How is the amount to be deferred calculated? 
 As of December 31, 2011, we will determine whether the value of your RSUs vesting on that date, plus your other non-performance based compensation for 2011, exceeds the $1 million deduction limit.
The value of your RSUs for this purpose will be determined by multiplying the number of fully vested RSUs by the closing selling price per Share on the NYSE on December 30, 2011 (the last day of trading in 2011). If your total non-performance
based compensation exceeds $1 million, we will divide the excess amount by the same price per Share to determine the number of Shares under your RSU award that must be deferred. 
 Similarly, on January 13, 2012 we will determine whether, and by how much, the value of your Founders Award RSUs fully vesting on that date, plus your other non-performance based compensation
projected for 2012, exceeds the $1 million deduction limit. The value of your Founders Award RSUs will be determined by multiplying the number of fully vested RSUs under that award by the closing selling price per Share on the NYSE on
January 13, 2012. If your total non-performance based compensation projected for 2012 exceeds $1 million, we will divide the excess amount by the same price per Share to determine the number of Shares under your Founders Award that must be
deferred. 
 For example, with respect to the your Founders Award RSUs fully vesting on January 13, 2012, if the value of one Share on
January 13, 2012 is $35 per share, your RSUs would be worth $            . If your other non-performance based compensation projected for 2012 is
$            , you would exceed the $1 million limit by $            . We would divide the
$             excess by $35 per share to determine the number of shares that must be deferred: $            
÷ $35 =              shares. 
 When will the deferred Shares be
paid? 
 Under Section 12 of your RSU Agreement, the deferred Shares will be settled after we have determined that deduction of the
payment will not be barred by Section 162(m). That means payment will be made to you after any one of the following events occurs: 
  

	 	•	 	 You terminate employment with Clearwater Paper and its affiliates; 

 

	 	•	 	 You continue employment with Clearwater Paper, but you cease to be a “covered employee,” i.e., you cease to be CEO or one of the top 3
highest paid executive officers other than the CFO; or 

  

	 	•	 	 You continue employment with Clearwater Paper and remain a “covered employee,” but you have room under the $1 million deduction cap to
receive additional non-performance based compensation at year-end. 

 In the first situation, we will deliver all of the
deferred Shares to you (subject to applicable withholding taxes) as soon as practicable after your termination of employment. While that delivery would normally occur within 60 days after your termination of employment, it is likely we will have to
delay delivery for at least 6 months after your termination of employment to comply with Section 409A of the Internal Revenue Code. 

  
 2 

 In the second situation, we will deliver all of the deferred Shares to you (subject to applicable
withholding taxes) at or near the end of the calendar year in which you ceased be a “covered employee,” but no later than 60 days after the end of that year. 
 In the third situation, we will perform a year-end calculation to determine the maximum number of Shares that can be delivered to you. We would first determine the maximum amount of RSU award compensation
that, when added to your other non-performance based compensation for that calendar year, would not exceed the $1 million limit, and then divide that amount by the closing selling price per Share on the NYSE on December 31 (or the last day of
trading, if earlier) of that year. The resulting number of Shares will be paid to you (subject to applicable withholding taxes) no later than 60 days after the end of that calendar year. Any Shares that cannot be paid to you at that time will
continue to be deferred until they can be paid to you under one of the three scenarios described above. 
 Will the deferred shares be
eligible for dividends? 
 Your deferred Shares will be credited with dividend equivalents if and when Clearwater Paper pays dividends on its
outstanding Shares. The dividend amounts will be deemed invested in additional Shares, which will be paid to you at the same time or times as the original deferred Shares are paid to you. 
 When is the compensation for deferred RSU awards reported for federal income tax purposes? 

Normally, when RSUs vest in a particular calendar year, we report on Form W-2 the fair market value of all of the underlying Shares as “wages”
subject to income tax and FICA tax withholding for that year. Since the settlement of a portion of your RSUs will be deferred, however, the tax reporting will be different. 
 The fair market value of the Shares that are being delivered to you (i.e., that are not being deferred) will be included in your Form W-2 for the year of vesting, and will be subject to both income tax
and FICA tax withholding. The Shares that are deferred will not be reported for income tax purposes until they are later paid to you. However, the fair market value of those deferred Shares will need to be reported for FICA tax purposes in the year
of vesting. There will be no additional FICA taxes payable on the deferred Shares when the Shares are later paid to you, even if the Shares have appreciated in value prior to that time. 
 We are permitted to treat the “wages” for the deferred Shares as arising at the end of the calendar year of vesting, when you should have exceeded Social Security wage base for the year
($106,800 for 2011). So the only portion of the FICA tax that should apply to the deferred Shares is the 1.45% Medicare tax. Arrangements will be made to have the 1.45% Medicare tax paid by withholding shares that are not being deferred. 

*            *          
  * 
 If you have any questions about this letter, please contact
                                 at
                    . 

  
 3 

 To confirm that you understand and agree with the deferral terms described in this letter, please sign and
date this letter where indicated below. You should retain a copy of this letter for your records, and return the signed original to
                                     at
                                    . 

Sincerely, 
 [Name] 

[Title] 
  

	
	Acknowledged and agreed:
	
	  

	 [Name]

	
	
Date:                    

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]